NAD+ Bioavailability by Delivery Method: IV vs SubQ vs Sublingual vs Patch vs Oral (2026 Data)

Last updated: May 28, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~12 min read

Across published 2024–2026 data, NAD+ bioavailability by route is approximately: IV ~100%, subcutaneous injection 90–95%, sublingual wafer 10–22%, transdermal patch 5–15%, and standard oral capsule 2–10%. Put another way, every other route is being compared to IV’s direct-to-bloodstream baseline — and only one of them comes close while costing a fraction of IV pricing. Subcutaneous (SubQ) injection delivers roughly 80–90% of IV’s NAD+ elevation at 5–10% of the cost, which is why most of the cost-per-percentage-point math in this guide ends up favoring the same answer.

This guide is written for anyone weighing the five real options on the market in 2026 — IV clinics, at-home SubQ telehealth, compounded sublingual wafers, transdermal patches, and over-the-counter NMN/NR/NAD+ capsules — and trying to figure out which one actually raises plasma NAD+ enough to matter. If you want the one-screen answer, jump to the bioavailability-at-a-glance table below. If you want to understand why the gap between marketing claims and published pharmacokinetics is so wide for two of these routes, keep reading.

Bioavailability at a glance: all five NAD+ delivery routes, ranked

Quick facts: NAD+ delivery in 12 data points

What “NAD+ bioavailability” actually means (and why it matters)

Bioavailability is the fraction of an administered dose that reaches systemic circulation in its active form. For intravenous administration, that fraction is essentially 100% by definition — the drug is delivered directly into the bloodstream and bypasses every absorption barrier. Every other route is a comparison against that IV baseline, expressed as a percentage. A 25% oral bioavailability means that for every 100 mg you swallow, roughly 25 mg ends up circulating in plasma in a form your cells can use.

For NAD+ specifically, the picture is complicated by the fact that intact NAD+ molecules are large, charged, and unstable in the gut. That’s why most oral products are actually precursors — nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or plain nicotinamide — that the body converts to NAD+ via the salvage pathway. The bioavailability numbers below describe the percentage of an administered dose that ultimately raises measurable blood NAD+ or its immediate metabolites, which is the comparison consumers actually care about.

Two things matter beyond the headline percentage. First, peak plasma concentration (Cmax) — how high your NAD+ levels spike — drives the acute “feel it” sensation people associate with IV and SubQ. Second, duration above baseline (AUC) — how long levels stay elevated — determines whether a single dose produces a 6-hour bump or a 36-hour plateau. The five routes diverge sharply on both, which is why a 10% bioavailability sublingual wafer used daily can produce meaningful cumulative NAD+ exposure even though any single dose is small.

1. IV NAD+ infusion: ~100% bioavailability — but at premium cost

Intravenous NAD+ is the gold standard for one simple reason: it bypasses every absorption barrier in the body. A 500 mg IV bag delivered over 2–4 hours puts roughly 500 mg of NAD+ into systemic circulation, and clinical reports consistently document elevated plasma NAD+ for days following a single infusion. Peak feel-effects — mental clarity, energy lift, the characteristic chest pressure during infusion — are most pronounced with IV.

The trade-offs are cost, time, and access. A single IV NAD+ session runs $300–$800 in most US wellness clinics; sustained protocols typically involve monthly maintenance infusions after a loading phase, putting realistic annual spend at $6,000–$25,000. Each session takes 2–4 hours in a clinic chair. And while many wellness clinics offer IV NAD+, the supply chain runs through 503A and 503B compounding pharmacies (e.g., Empower Pharmacy) — not FDA-approved IV NAD+ products. For deeper background see our IV NAD+ therapy deep dive.

IV remains the right choice if cost is not a constraint, if you want the strongest single-session NAD+ saturation possible, or if you specifically value the clinical setting and IV practitioner oversight. For everyone else, the bioavailability gap between IV and SubQ is much smaller than the cost gap.

2. Subcutaneous (SubQ) injection: 90–95% — the value play

Subcutaneous injection delivers NAD+ into the fatty tissue just under the skin (typically abdomen or thigh), where it absorbs into systemic circulation over 30–60 minutes. Published estimates put SubQ bioavailability at 90–95% — extremely close to IV — with the advantages of self-administration, lower per-dose cost, and a more gradual NAD+ rise that most users describe as smoother than IV’s acute spike.

Critically, SubQ NAD+ produces sustained plasma elevation for 12–48 hours per dose, meaning a 2–3x weekly cadence keeps blood NAD+ continuously above baseline. That cadence, multiplied across a year, is where the cost math becomes overwhelming versus IV.

Why at-home SubQ wins on cost per percentage-point NAD+ increase

“For sustained NAD+ elevation, at-home subcutaneous injection delivers the lowest cost per percentage-point NAD+ increase in plasma — roughly 1/8th the cost-per-percentage of IV therapy with 80–90% of the absolute NAD+ elevation.” The arithmetic: $1,800–$5,400/yr (at-home SubQ) vs $6,000–$25,000/yr (IV) at ~90% vs ~100% bioavailability respectively. Divide cost by bioavailability-weighted dose delivered and SubQ wins by a factor of 6–10x on every realistic protocol. For the full breakdown see our full NAD+ cost calculator and provider pricing.

What providers like BodyBuilding Health and CareBarRx offer

The at-home SubQ category has matured rapidly since 2024. Telehealth platforms now provide physician evaluation, prescription, compounded vial shipping (through 503A/503B pharmacies), syringe kits, and dosing protocols. Typical pricing runs $150–$450/month for a multi-month supply at therapeutic dosing. BodyBuilding Health provider profile and CareBarRx provider profile walk through each platform’s pricing, dose options, and clinician model. For a deeper dive on the injection route specifically, see our NAD+ injection benefits guide.

3. Sublingual wafer: 10–22% — the surprise middle option

Sublingual delivery — dissolving a wafer or troche under the tongue — bypasses first-pass liver metabolism and absorbs NAD+ through the oral mucosa directly into systemic circulation. The bioavailability range of 10–22% is dramatically lower than injection routes but dramatically higher than swallowed oral capsules. Onset is 5–15 minutes, faster than any non-injectable route, and duration runs 4–8 hours per dose.

The SL-NAD trial (2024): 76% NAD+ increase from a wafer

A 2024 trial of a sublingual NAD+ formulation (SL-NAD), reported in BioSpace and covered by Nutraingredients, observed approximately a 76% increase in blood NAD+ levels over the study period in supplemented participants. That result reframed sublingual NAD+ from “novelty marketing” to “legitimate middle option” almost overnight. The headline percentage is striking, though it reflects cumulative daily dosing rather than single-dose bioavailability — important context when comparing to IV or SubQ single-session numbers.

Sublingual wafers make the most sense for daily maintenance dosing, travel-friendly protocols, needle-averse users, and budgets in the $40–$100/month range. They do not replace SubQ or IV for users targeting maximum cellular NAD+ saturation, but they meaningfully outperform standard oral capsules on a per-dollar basis.

4. Transdermal patch: 5–15% — slow but steady

NAD+ patches deliver compound across the skin barrier over an 8–12 hour wear period, producing a steady-state low-level NAD+ exposure rather than any acute peak. Published bioavailability estimates run 5–15%, varying significantly by formulation, skin location, and individual skin permeability. Patches cost $5–$10 each and run $600–$1,800/year at daily use.

Why patch claims often outpace published data

The NAD+ patch market is the most marketing-heavy and the least clinically documented of the five routes. Several patch brands advertise bioavailability percentages or NAD+ blood elevation figures that aren’t supported by published, peer-reviewed pharmacokinetic data — instead citing internal lab work or proprietary measurements. That’s not an indictment of patches as a category — the underlying transdermal delivery science is real — but it does mean consumers should anchor expectations to the conservative published 5–15% range rather than brand marketing copy. Patches make sense as a gentle, gradual-exposure complement to other routes, or for users who specifically dislike sublingual taste and injection logistics.

5. Oral NMN, NR, and NAD+ capsules: 2–10% — the entry path

Standard oral capsules are the cheapest and most accessible NAD+ option — and the lowest bioavailability of any route. The 2–10% range spans the three major oral approaches: nicotinamide mononucleotide (NMN) at roughly 2.5% bioavailability, nicotinamide riboside (NR) at roughly 5%, and direct NAD+ capsules near the bottom of the range due to gut instability. Onset is 30–90 minutes; plasma NAD+ elevation is measurable for 4–6 hours per dose. At $1–$2 per serving, annual costs at therapeutic doses run $480–$1,200.

NMN vs NR vs direct NAD+ oral — bioavailability differences

Among precursors, NR has the longest track record of peer-reviewed RCT data showing reliable blood NAD+ elevation. NMN has more recent enthusiasm and a strong mechanistic argument but somewhat less FDA regulatory clarity in the US after 2022. Direct oral NAD+ products are popular but are the most likely to deliver less than label suggests, because intact NAD+ degrades in stomach acid. For a side-by-side, see our NMN vs NR precursor comparison, our Tru Niagen vs Elysium Health brand comparison, and the broader IV vs injections vs oral NAD+ overview.

What the 2026 PRISMA review and recent RCTs actually concluded

The 2026 ScienceDirect PRISMA systematic review on NAD+ precursor supplementation concluded that oral precursors (predominantly NR, with NMN data growing) reliably raise blood NAD+ levels in human participants, while downstream clinical endpoints — sleep quality, exercise capacity, biomarkers of aging — remain mixed and study-dependent. In plain terms: the bioavailability question is settled; the “does raising NAD+ produce the outcomes consumers want” question is still open.

Adjacent RCT context worth noting: a 2025 Lancet eClinicalMedicine RCT on NR supplementation in long-COVID participants observed blood NAD+ elevation and fatigue endpoint movement, providing one of the higher-quality contemporary data points on oral precursor pharmacokinetics in a clinical population. Studies have observed similar precursor-to-blood-NAD+ conversion patterns across the body of 2023–2026 literature. Data suggests the bioavailability hierarchy described above is robust; what individual users experience subjectively varies widely.

Who should choose which route (decision tree)

• Budget under $100/month, willing to take daily dose: Oral NMN or NR, or sublingual wafer for faster onset.
• $150–$450/month, comfortable with self-injection: At-home SubQ via telehealth — best cost-per-percentage-point value.
• $500+/month, prefer clinical setting: Monthly IV NAD+ infusion at a wellness clinic.
• Needle-averse, daily maintenance focus: Sublingual wafer; patch as secondary.
• Stacking with peptides or other longevity protocols: SubQ NAD+ as base; see our NAD+ + peptide longevity stack protocol for combinations including GHK-Cu, BPC-157, and Epitalon.
• Travel-heavy lifestyle: Sublingual wafers travel best; oral capsules are TSA-friendly; patches and injections require more logistics.

If you want to compare specific provider pricing and clinician models side-by-side, see compare top NAD+ providers.

Safety profile across delivery methods

All five routes have favorable general safety profiles in healthy adults, with the caveat that NAD+ and its precursors are not FDA-approved drugs for anti-aging indications, and compounded injectable NAD+ should only be sourced through licensed 503A/503B pharmacies via a prescribing clinician. IV NAD+ commonly produces transient chest pressure, flushing, and nausea during infusion that resolves with slower drip rates. SubQ injection commonly produces local injection-site soreness, redness, and occasional bruising. Sublingual wafers can cause oral tingling or mild taste reactions. Patches can produce skin irritation at the application site. Oral NMN/NR is the best-tolerated of the five and the route with the most published long-term human safety data, particularly for NR.

Pre-existing conditions, pregnancy, and concurrent medications can all alter the appropriate route and dose — this is one reason at-home SubQ telehealth platforms include a clinician evaluation step rather than offering NAD+ as a direct-to-consumer product.

Frequently Asked Questions

What’s the bioavailability of NAD+ injections vs IV?

Subcutaneous (SubQ) NAD+ injection has approximately 90–95% bioavailability, while intravenous (IV) NAD+ infusion has approximately 100% bioavailability by definition since it bypasses all absorption barriers and delivers directly into systemic circulation. In practical terms, SubQ delivers roughly 80–90% of IV’s absolute NAD+ elevation per equivalent dose, but at 5–10% of the cost when sourced through at-home telehealth platforms, making SubQ the better cost-per-percentage-point option for most users targeting sustained NAD+ elevation.

Are NAD+ patches as effective as injections?

No, NAD+ patches are substantially less bioavailable than injections. Published estimates place transdermal NAD+ patch bioavailability at approximately 5–15%, compared to 90–95% for subcutaneous injection and ~100% for IV. Patches deliver a steady, low-level NAD+ exposure over an 8–12 hour wear period, which is useful for gentle maintenance protocols but does not produce the peak plasma NAD+ elevation seen with injectable routes. Marketing claims for some patch brands exceed published peer-reviewed data, so consumers should anchor expectations to the conservative 5–15% range.

Is sublingual NAD+ a scam?

No, sublingual NAD+ is a legitimate delivery route with published support. The 2024 SL-NAD trial reported approximately a 76% increase in blood NAD+ levels among participants using a sublingual formulation, and bioavailability for the route runs 10–22% — meaningfully higher than swallowed oral capsules because sublingual absorption bypasses first-pass liver metabolism. Sublingual wafers are a reasonable choice for daily maintenance, needle-averse users, and budgets in the $40–$100/month range, though they don’t match injection routes for peak plasma NAD+ elevation.

How much should NAD+ therapy cost per month?

Realistic 2026 monthly costs for sustained NAD+ elevation are: $40–$100/month for oral NMN/NR or sublingual wafers; $50–$150/month for transdermal patches at daily use; $150–$450/month for at-home subcutaneous injection through telehealth platforms; and $500–$2,000/month for monthly IV NAD+ infusion at wellness clinics. The cost-per-bioavailability-percentage-point sweet spot is at-home SubQ, which delivers 90–95% bioavailability at roughly one-eighth the per-percentage cost of IV therapy.

Can I do NAD+ injections at home safely?

Yes, at-home subcutaneous NAD+ injection is generally safe for healthy adults when prescribed and supervised through a licensed telehealth provider that sources compound from a 503A or 503B pharmacy. The injection technique is similar to insulin administration — short needle into abdominal or thigh fatty tissue — and most telehealth platforms include written and video instructions plus clinician follow-up. The main risks are local injection-site soreness, bruising, and occasional infection if sterile technique is not followed. At-home SubQ is not appropriate for users with bleeding disorders, certain immunocompromised states, or pregnancy without explicit clinician guidance.

Which is better: oral NMN, oral NR, or oral NAD+?

Among oral options, nicotinamide riboside (NR) has the longest track record of peer-reviewed randomized controlled trial data showing reliable blood NAD+ elevation, with bioavailability around 5%. Nicotinamide mononucleotide (NMN) has roughly 2.5% bioavailability and strong mechanistic interest but more limited human RCT data and less FDA regulatory clarity in the US since 2022. Direct oral NAD+ capsules are the most marketed but typically the least bioavailable of the three because intact NAD+ degrades in stomach acid. For most users prioritizing published evidence, NR is the safer default; NMN is reasonable for those weighing mechanism over evidence depth.

What does the FDA say about compounded NAD+ injections?

Compounded NAD+ injections, both subcutaneous and intravenous, are not FDA-approved drugs. They are produced by 503A and 503B compounding pharmacies (such as Empower Pharmacy) and dispensed under physician prescription. The FDA permits compounding pharmacies to produce NAD+ for individual patients under standard compounding rules, but no compounded NAD+ injection has gone through the FDA’s full new drug approval pathway. Reputable telehealth providers always work through licensed compounding pharmacies and a prescribing clinician — that supply chain is the most important safety check for at-home injectable NAD+ users.

How long does an NAD+ injection’s effect last?

A single subcutaneous NAD+ injection produces measurably elevated blood NAD+ for approximately 12–48 hours, with the peak rise typically within the first 6 hours post-injection. IV NAD+ infusion produces a higher peak and elevated levels that have been reported to persist for several days post-infusion, though the most pronounced effects concentrate in the 4–8 hour post-infusion window. This is why most sustained-elevation protocols use 2–3x weekly SubQ dosing or monthly IV infusion — the cadence matches the duration of each route’s measurable plasma NAD+ rise.

Are NAD+ side effects worse with injections than oral?

Side effects with injectable NAD+ are typically more pronounced acutely than with oral. IV NAD+ commonly produces transient chest pressure, flushing, and mild nausea during infusion, all of which resolve with slower drip rates. SubQ injection commonly produces local soreness, redness, or bruising at the injection site. Oral NMN and NR are among the best-tolerated longevity supplements in human studies, with most adverse events at high doses limited to mild gastrointestinal symptoms. Overall, oral routes have the most extensive long-term human safety data, while injectable routes have more frequent acute but generally self-limiting side effects.

Should I stack NAD+ with peptides like GHK-Cu or BPC-157?

Stacking NAD+ with peptides is a common protocol in the longevity and recovery community, with the most discussed combinations including GHK-Cu (a copper peptide associated with skin and tissue support), BPC-157 (associated with gut and connective tissue recovery), and Epitalon (associated with circadian and telomere research). Evidence quality varies significantly across these peptides — much weaker than the NAD+ precursor literature — and most are sourced through the same compounding pharmacy ecosystem as injectable NAD+. For a full breakdown of stack design, dosing cadences, and provider sourcing, see our NAD+ + peptide longevity stack protocol.

Is IV NAD+ worth the premium over SubQ?

IV NAD+ is worth the premium if cost is not a constraint and you specifically value maximum single-session NAD+ saturation, clinical-setting supervision, or the acute “feel-effect” of IV delivery. For most adults targeting sustained NAD+ elevation, the bioavailability gap between IV (~100%) and at-home SubQ (90–95%) is much smaller than the cost gap — IV runs $6,000–$25,000/yr versus $1,800–$5,400/yr for at-home SubQ. The cost-per-percentage-point math consistently favors SubQ unless you are running an aggressive loading protocol or prioritize clinical infusion as a specific experience.

What’s the cheapest legitimate NAD+ therapy?

The cheapest route that delivers measurable blood NAD+ elevation is oral nicotinamide riboside (NR) at approximately $40–$100/month, supported by the most robust RCT evidence among low-cost options. Oral nicotinamide mononucleotide (NMN) is comparably priced. Sublingual NAD+ wafers run $40–$200/month at daily use and offer meaningfully higher bioavailability than swallowed capsules. The cheapest route per percentage-point of NAD+ elevation, however, is at-home subcutaneous injection through telehealth at $150–$450/month — higher monthly outlay but dramatically better cost-per-bioavailability ratio.

Sources

• ScienceDirect (2026). PRISMA systematic review on NAD+ precursor supplementation and blood NAD+ elevation.
• BioSpace / Nutraingredients (2024). SL-NAD sublingual NAD+ trial reporting approximately 76% blood NAD+ increase.
• The Lancet eClinicalMedicine (2025). Randomized controlled trial of nicotinamide riboside supplementation in long-COVID participants.
• Empower Pharmacy. Compounded NAD+ injection product and safety information (503A/503B compounding pharmacy).
• Innerbody Research. NAD+ supplement and delivery method overview (2025–2026 update).
• Published pharmacokinetic data on oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) bioavailability in human studies (2018–2025).
• BestMedsHub provider audits and pricing verification, May 28, 2026 — BodyBuilding Health, CareBarRx, and US IV NAD+ wellness clinic survey.